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Introduction
Some breast cancers require oestrogens for growth and, 
if deprived of these hormones, will regress. Consequently, 
oestrogen deprivation therapy is a major treatment 
strategy for hormone-dependent breast cancer. Th ere are 
various forms of endocrine therapy but recently agents 
inhibiting the aromatase enzyme, which catalyzes the 
conversion of androgens to oestrogen, have been in-
creasingly used [1]. Th ese have evolved from rational 
drug development, which has generated inhibitors with 
exceptional potency and speciﬁ city [2]. In postmeno-
pausal women, drugs such as letrozole, anastrozole and 
exemestane can inhibit aromatization of androgen in vivo
by >99% [3], often decrease circulating oestrogens to un-
detectable levels [3,4] and, in hormone-dependent breast 
cancers, reduce tumour proliferation [5,6] and growth 
[7,8]. Th ird-generation aromatase inhibitors (AIs) are 
now front-line treatments for breast cancer [1]. However, 
response rates range between 35 and 70% in neoadjuvant 
studies [9,10], and beneﬁ ts may be lower in advanced 
disease [11]. Acquired resistance after initial successful 
treatment also occurs [12]. Consequently, resistance is a 
major obstacle and optimal clinical management would 
beneﬁ t from early identiﬁ cation of resistance and the 
mechanisms by which resistance occurs. Patients with 
clinically resistant cancers could then be spared unneces-
sary side eﬀ ects and ineﬀ ective treatment. Knowledge of 
the underlying reason for resistance would also facilitate 
the development and implementation of new therapies 
by which to bypass or reverse resistance. Th e present 
review will address these issues by i) distinguishing 
between diﬀ erent types of resistance and identifying 
potential complications and confounders, ii) summariz-
ing key clinical observations and iii) integrating these 
with biological/molecular studies performed on tumours 
clinically resistant to AIs.
Types of resistance
Before considering speciﬁ c issues relating to resistance, 
some brief deﬁ nitions of diﬀ erent forms of resistance are 
presented.
Clinical versus other forms of resistance
Clinical ‘resistance’ to AIs is usually perceived as a lack of 
growth inhibition by AI treatment in that the therapy is 
ineﬀ ective in causing a decrease in tumour size. However, 
AI treatment often results in molecular (and pathological) 
changes in clinically resistant tumours [13,14]. Clinical 
resistance therefore needs to be distinguished from other 
forms of resistance, including that in which AI therapy 
fails to elicit any form of response (in the same way as 
dependence should be separated from sensitivity).
Primary versus acquired resistance
Resistance may be subdivided into primary (or de novo) 
and secondary to an initial treatment response (or 
acquired). Although having clinical implications, primary 
and acquired resistance may not be separate entities and 
underlying mechanisms of resistance may be shared. 
However, the inference is that ‘acquired’ resistance is the 
result of inductive changes or clonal selection caused by 
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treatment. Molecular changes that could impact on 
eﬀ ectiveness of therapy have been observed following AI 
treatment [15,16].
Cross-resistance and non-cross-resistance
Some tumours resistant to AIs also appear non-
responsive to other forms of endocrine therapy (that is, 
they are cross-resistant [17]); other AI resistant tumours 
are sensitive to other endocrine therapies (that is, there is 
no cross-resistance [18,19]). Non-cross-resistance can be 
subtle where, for example, tumours may be resistant to 
one AI (or class of AIs) but respond to another [20,21].
Observations from clinical trials
Knowledge contributing to the understanding of resis-
tance to AI may be derived from i) randomised clinical 
trials comparing AIs with other forms of endocrine 
therapies, ii) randomised studies in which AIs have been 
compared with a combination of AIs plus a targeted 
agent and iii) studies in which patients with AI-resistant 
tumours have been given further treatment.
Comparison of AIs with other forms of endocrine therapies
Novel, third generation AIs (anastrozole, letrozole and 
exemestane) have greater eﬃ  cacy and improved safety 
proﬁ les compared with their predecessors when em-
ployed as treatment for hormone-responsive postmeno-
pausal breast cancers [2,3,8]. Randomized clinical trials 
also show that third generation AIs are equivalent or 
superior in eﬃ  cacy to tamoxifen [9-11,22,23] and may be 
eﬀ ective in tamoxifen-resistant advanced breast cancer 
[24,25]. Despite the latter observation, prior resistance to 
other forms of endocrine therapy is associated with a 
decreased probability of response to an AI [26].
It is worth commenting on the time taken to elicit 
clinical response. Several neoadjuvant protocols show that 
longer treatment with an AI results in additional clinical 
beneﬁ t [27,28]. It is thus possible that a minority of 
apparently resistant tumours may be sensitive to the action 
of AIs but extended treatment is required before clinical 
response becomes manifest. Th is contrasts with the speed 
of response generally observed following chemotherapy.
Comparison of AIs with a combination of AIs plus a 
targeted agent
Clues to potential resistance mechanisms may be gleaned 
from studying agents that signiﬁ cantly change response 
rates when given in combination with AIs. Th e most 
informative studies are those involving selected targeted 
agents for which there is a rationale related to AI resistance. 
Targets include type I growth factor receptors, epidermal 
growth factor receptor, human epi dermal growth factor 
receptor (HER)2 and phospho inositide 3-kinase/mam-
malian target of rapamycin (mTOR) inhibitors. Results 
from several of these clinical trials have recently been 
reported. For example, a pre operative study of letrozole 
with or without the mTOR inhibitor everolimus reported 
greater tumour shrinkage for the combination [29]. 
Furthermore, marked antiproli ferative responses occurred 
in 57% of patients in the combination everolimus arm 
compared with 30% in the letrozole alone arm. Th is 
suggests that, in some tumours, AKT signalling is asso-
ciated with letrozole resistance, an inﬂ uence that may be 
abrogated by phosphoinositide 3-kinase/mTOR inhibitors.
Other combinations involve therapies that target the 
HER family of growth factor receptors using either 
antigrowth factor-receptor antibodies (for example, tras-
tu zumab) or small molecule tyrosine-kinase inhibitors 
(such as geﬁ tinib and lapatinib). A randomized trial of 
ﬁ rst-line geﬁ tinib plus anastrozole versus anastrozole 
alone in women with oestrogen receptor (ER)-positive 
advanced breast cancer reported that patients who 
received the combination therapy experienced signiﬁ -
cantly longer progression-free survival (PFS) and an 
improvement in clinical beneﬁ t rate, but a lower response 
rate [30,31]. In neither of the mentioned trials using the 
combination of geﬁ tinib plus anastrozole were patients 
selected on the basis of overexpression of growth factor 
receptors. How ever, two studies have included HER-2 
status in selection criteria. Th us, in patients with known 
ER-positive/HER2-positive tumours, the addition of 
lapatinib to letrozole signiﬁ cantly reduced the risk of 
progression and im proved median PFS; clinical beneﬁ t 
rate was also signiﬁ  cantly greater for the combination 
[32]; a preplanned analysis was also able to show an 
impact of combination therapy on PFS in the HER2-
negative population. Finally, a randomized phase III trial 
in patients with known hormone receptor-positive/
HER2-positive metastatic breast cancer recently reported 
a doubling of PFS with the addition of trastuzumab to 
anastrozole compared with anastrozole alone [33]. In 
these combination studies, it is possible that the 
additional beneﬁ t of targeted therapy is separate from the 
endocrine eﬀ ects of AIs. However, preclinical studies and 
measurements of biological markers suggest synergy or 
cross-talk between signalling systems. Th e hypothesis is 
therefore that acquired resistance to AIs in patients with 
ER-positive/HER2-negative tumours may be caused by 
adaptive epidermal growth factor receptor or HER2 
upregulation and this might be prevented or delayed by 
agents directed against these targets.
Further treatment in patients with AI-resistant tumours
Important information about the nature of AI resistance 
may be derived from clinical studies in which patients 
with tumours resistant to an AI are given further treat-
ment. It is especially interesting to review investigations 
in which therapy has involved another AI (Table 1). For 
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example, responses to formestane have been reported in 
patients failing aminoglutethimide [34,35], and clinical 
response to exemestane may follow the development of 
resistance to non-steroidal AIs [36] and, conversely, 
patients progressing after exemestane therapy have been 
shown to derive further beneﬁ ts from treatment with 
letrozole or anastrozole [37]. Th ese clinical studies 
indicate at least a partial non-cross-resistance between 
steroidal AIs and non-steroidal AIs [20,31,38]. In general, 
objective response rates with the second-line agent are 
not high, but clinical beneﬁ t is observed in 20 to 55% of 
patients regardless of the treatment sequence (for 
example, non-steroidal AI followed by steroidal AI or 
steroidal AI followed by non-steroidal AI). More recently, 
results have become available from the Evaluation of 
Fulvestrant versus Exemestane Clinical Trial (EFECT) in 
which patients with advanced hormone receptor-positive 
breast cancer refractory to a non-steroidal AI have been 
randomized to receive either fulvestrant or exemestane 
[39]. In the exemestane arm, objective response rate was 
observed in 6.7% and clinical beneﬁ t in 31.5% (the 
corresponding ﬁ gures for the fulvestrant arm were 7.4 
and 32%). Although many of the studies contain small 
numbers of patients, evidence is consistent and indicates 
that patients whose disease becomes resistant to one AI 
may still respond to a diﬀ erent class of AI. Th e molecular 
mechanisms underpinning AI non-cross-resistance are 
not immediately apparent (AIs have a common mecha-
nism of action). However, the phenomenon and sequen-
tial responses to anti-oestrogens such as fulvestrant [39] 
suggest that growth in a proportion of AI-resistant 
tumours may be maintained by signalling through a 
functioning ER pathway.
Endocrine and molecular markers
Th e understanding of mechanisms of AI resistance has 
also been furthered by identiﬁ cation of i) molecular and 
endocrine markers that might distinguish between 
resistant and responsive cancers, ii) changes induced by 
AI therapy that might be associated with an AI-resistant 
phenotype and iii) genetic signatures and patterns that 
illustrate diversity of resistance.
Endocrine and molecular markers
Oestrogen receptors
A major cause of resistance to AIs and other endocrine 
therapies is absence of functional ER in tumours. For 
example, in the P024 neoadjuvant trial of letrozole versus 
tamoxifen [23], a small number of ER-negative tumours 
(protocol violators) were entered into the study and none 
responded to either drug. Patients with ER-negative 
tumours should not be oﬀ ered therapy. However, many 
ER-positive tumours also do not respond to AIs. Th e 
challenge is how to discriminate accurately and on an 
individual basis which ER-positive tumours respond to 
treatment and those that do not.
HER2
HER signalling can result in ER phosphorylation (a 
critical step in ER activation) even in the absence of 
oestrogen [40]. However, the situation with regard to 
tumour HER2 overexpression and resistance to AIs is 
complicated. In the neoadjuvant setting, clinical response 
rates to AIs are similar in HER2-positive and -negative 
tumours [41,42]. At the same time, AIs often fail to 
reduce proliferation in ER-positive/HER2-positive breast 
cancers even amongst those that display a clinical 
response [41,43]; this suggests that growth factors other 
than oestrogen are driving proliferation, limiting the 
beneﬁ ts of AIs in HER2-overexpressing tumours (this 
observation would also account for the poorer long-term 
outcomes in HER2-overexpressing breast cancer as 
reported in adjuvant trials with AIs [44,45]). Further-
more, numbers of ER-positive/HER2-positive breast 
cancers are small [46] and the pathway is unlikely to 
account for AI resistance in most tumours.
Table1. Sequential treatment using diff erent classes of aromatase inhibitors 
   Objective Clinical Time to progression
Initial treatment Second treatment n response (%) benefi t (%) (months) Reference
Anastrozole or letrozole Exemestane 23 8.7 43.5 5.1 [37]
Exemestane Anastrozole or letrozole 18 22.2 55.6 9.3 [37]
Anastrozole Exemestane 12   4.4 [73]
Exemestane Anastrozole 11   1.9 [73]
Anastrozole Exemestane 50 8.0 44.0 5.0 [74]
Anastrozole or letrozole Exemestane 114 5.0 46.0 4.5 [75]
Anastrozole or letrozole Exemestane 31 19.4 54.8 3.2 [76]
Anastrozole or letrozole Exemestane 30 0.0 46.6 4.0 [77]
Anastrozole or letrozole Exemestane 60 20.0 38.3 3.2 [78]
Anastrozole or letrozole Exemestane 105 4.8 20 3.2 [36]
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Other potential markers
Genetic polymorphisms have been identiﬁ ed and charac-
terised in the aromatase gene and may have functional 
inﬂ uences on the interaction between the enzyme 
protein, its substrate and inhibitors [47]. Th us, it is of 
interest that Wang and colleagues [48], examining 
tumour from breast cancer patients, reported that two 
tightly linked SNPs (rs6493497 and rs7176005) were 
signi ﬁ cantly associated with a greater change in aroma-
tase activity after AI treatment and that, in a separate 
group of cases, these two same SNPs were associated 
with higher plasma oestradiol levels in patients pre-AI 
and post-AI treatment. Th e authors hypothesised that 
SNPs in the CYP19 gene may alter the eﬀ ectiveness of AI 
therapy in the neoadjuvant setting. Others have reported 
interesting ﬁ ndings with regard to a SNP (rs4646) located 
in the 3’ untranslated region of the aromatase CYP19 
gene. Th us, Colomer and colleagues [49] found that in 
patients with hormone receptor-positive metastatic 
breast cancer treated with the aromatase inhibitor letro-
zole, time to progression was signiﬁ cantly improved in 
patients with the rs4646 variant compared with the wild-
type gene (17.2 versus 6.4 months; P = 0.02). In contrast, 
Garcia-Casado and colleagues [50] analysed DNA from 
peripheral blood of patients oﬀ ered neoadjuvant letro-
zole; they showed that those carrying genetic variants of 
rs4646 had a lower PFS than patients homozygous for the 
reference variant. Ribosomal proteins have also been 
associated with resistance to an AI. Th us, mRNA ex-
pression of several ribosomal proteins has been reported 
to be signiﬁ cantly lower in letrozole-resistant tumours 
compared with responsive cases [51]. A study using letro-
zole alone or in combination with chemotherapy [52] 
examined a group of tumour proteins involved in apop-
tosis, cell survival, hypoxia, angiogenesis, and growth 
factor and hormone signalling; increased hypoxia-
inducible factor-1 alpha and P44/42 mitogen-activated 
protein kinase (MAPK) were associated with resistance. 
Lastly, over expression of low-molecular-weight cyclin E 
has been claimed to bypass letrozole-induced G1 arrest 
and thereby produce resistance [53]. Whilst all these 
studies are potentially important, being derived from 
appropriate clinical material and involving markers that 
could functionally impact on resistance mechanism for 
AIs, it should be noted that results have usually been 
based on a single series of breast cancers; there is an 
immediate need for independent conﬁ rmation using 
diﬀ erent cohorts of tumours.
Changes induced by aromatase inhibitor therapy
Recently, several studies have exploited preoperative or 
neoadjuvant protocols employing AIs to determine mole-
cular responses to treatment [15,16,54-56]. Results are 
generally consistent. Th us, AIs suppressed expression of 
classical oestrogen-dependent and proliferation-related 
genes, such as TFF1, KIAA0101, PDZK1, AGR2, ZWINT, 
IRS1, CDC2, CCND1, CCNB1, NUSAP1 and CKS2. Th e 
most consistently upregulated genes were enriched by 
‘stromal’ signatures, including speciﬁ c types of collagens 
(COL3A1, COL14A1, COL1A2), members of a small 
leucine-rich proteoglycan family (DCN, LUM and ASPN), 
genes associated with cell adhesion and intercellular 
matrix turnover (MMP2, CD36, CDH11, ITGB2, SRPX, 
SPON1, DPT) and immune-response-associated genes 
(COLEC12, IL1R1, C1R, TNFSF10). In the neoadjuvant 
studies, molecular changes could be related to clinical 
res ponse [14,51,55,57]. Although classical markers of 
oestro gen sensitivity and proliferation were generally 
reduced with treatment in responsive tumours, their ex-
pression was also frequently decreased in resistant 
tumours [13,14]; consequently they diﬀ erentiated poorly 
between response and resistance to AIs. In terms of 
genes that changed with therapy and also distinguished 
between responsive and resistant tumours, Miller and 
colleagues [51] drew attention to structural constituents 
of ribosomes (Figure 1). Th us, responsive tumours 
showed higher expression of ribosomal proteins before 
treatment and decreased expression after 2 weeks of 
letrozole therapy but, by contrast, baseline expression of 
ribosomal proteins was low in resistant tumours and was 
increased by treatment.
Mello-Grande and colleagues [55] examined gene 
expression proﬁ ling and response to neoadjuvant treat-
ment with anastrozole and observed an enrichment of 
induction of T-cell anergy, positive regulation of andro gen 
signalling, synaptic transmission and vehicle traﬃ  ck ing in 
non-responding tumours. In a further study, up regulation 
of ER coactivator mRNA and HER2 was observed during 
neoadjuvant treatment with either letrozole or anastrozole 
[56]. Th is is of interest since these are factors that inﬂ uence 
oestrogen signalling and could potentially mediate 
acquired resistance to AIs.
It is self-evident that to diﬀ erentiate between respon-
sive and resistant tumours on the basis of changes on 
treatment, it will be necessary to sample tumours on 
multiple occasions. A further corollary is that if adaptive 
changes during treatment result in resistance, it is likely 
that there will be a necessity for a re-biopsy at time of 
recurrence/resistance to elucidate the nature/mechanism 
of resistance.
Molecular diversity of aromatase inhibitor resistance
Gene proﬁ ling data suggest that AI-resistant tumours are 
more diverse than responsive cases [57]. Resistant tumours 
can also be divided into subgroups using treatment-
induced expression changes in genes associated with 
oestrogen regulation or proliferation [13]. Th us, letrozole-
resistant tumours could be grouped into cases that 
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showed generally no molecular changes, decreases in 
oestrogen-regulated genes but not those related to 
proliferation, or general decreases in both oestrogen-
regulated and proliferation genes (Figure 2). Some specu-
lation on these ﬁ ndings is merited. Th us, cases with no 
general change in gene expression in response to 
letrozole appear to have the classical phenotype of 
oestrogen insensitivity. Th ere are two major reasons for 
this. First, it is possible that although the tumours possess 
ER, the receptors are non-functional and not functionally 
connected to downstream signalling. However, it is also 
possible that the lack of molecular changes may be 
because the drug has failed to have endocrinological 
eﬀ ects and tumour is not being exposed to oestrogen 
deprivation. Measurements of circulating and intra-
tumoural oestrogens would distinguish between these 
possibilities. Th e diﬀ erential phenotype in which expres-
sion of oestrogen-regulated genes was mostly reduced 
but that for proliferation genes was generally increased 
illustrates a disconnection between expression of oestro-
gen signalling and proliferation genes. It is clear that 
these tumours are seeing oestrogen deprivation as 
evidenced by the decreases in oestrogen-regulated genes 
but it appears that proliferation (and therefore tumour 
growth) is being controlled by non-oestrogenic pathways. 
Reduced expression of both markers of oestrogen 
regulation and proliferation is a paradoxical phenotype in 
cases of clinical resistance. Whilst these tumours are 
categorized as clinical non-responders, they do react to 
oestrogen deprivation at molecular and proliferative 
levels. Th e major issue to clarify is why molecular and 
proliferative responses associated with oestrogen 
Figure 1. Eff ects of neoadjuvant treatment with letrozole on changes (within 10 to 14 days) in microarray expression of ribosomal 
proteins. (a) Average changes for the total group, the responding group and the non-responding group. Error bars represent standard errors of the 
mean. (b) Changes in individual tumours. Red represents an increase in expression and green a decrease. Brightness of colour indicates degree of 
change, with the brightest colours representing the greatest change. The RPLP0 gene is represented by four probe sets.
(a)
(b)
       Non-Responders                                                                        Responders
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depriva tion by letrozole do not translate into clinical 
responses. Th ere are several potential reasons. First, it may 
reﬂ ect limitations and inaccuracy of clinical measure-
ments. Current clinical criteria for response assessment 
are often based on arbitrary empirical thresholds that may 
not accurately reﬂ ect biology of tumour response. For 
example, tumours shrinking with treatment are routinely 
categorized as ‘clinically resistant’ if the decrease fails to 
reach 50% reduction in tumour volume during therapy. 
Th ese tumours might have become clinical responders 
with extended treatment. It should also be noted that 
treatment did not decrease expression of these genes to 
zero and, after therapy, expression is still measurable. 
Hence, it could be that the reductions in proliferation are 
not suﬃ  cient to produce a clinical response in the absence 
of other changes, such as an increase in cell death.
Th e authors suggest that a systematic molecular 
characterisation of changes in expression of classical 
oestrogen-regulated and proliferation-associated genes 
with short-term exposure to AIs will provide funda-
mental information relating to underlying mechanism of 
resistance and allow a more rational clinical management 
in individual patients. A prospective study is recom-
mended for the future.
Mechanisms of resistance
It is clear that there are a multitude of mechanisms that 
could account for breast cancers appearing/being 
resistant to therapy with AIs [2,58]. Th is could also be 
deduced theoretically by considering the classical multi-
step pathway of oestrogen stimulation of breast cancer 
growth and mechanism of action of AIs as illustrated in 
Figure  3. Because the inﬂ uence of AIs may be compro-
mised or bypassed at each step in the pathway, there are 
multiple opportunities for resistance. Th ese will be 
considered under the headings illustrated in Figure 3: 
(A)  ineﬀ ective inhibition of aromatase; (B) alternative 
sources of oestrogen/oestrogenic hormones; (C) inherent 
oestrogen insensitivity (non-functional ER); (D) ligand-
independent acti va tion of oestrogen signalling pathways; (E) 
oestrogen signalling disconnected from tumour prolifera-
tion and growth; (F) enhanced cell survival; and outgrowth 
of hormone-insensitive cellular clones (not illustrated).
Ineff ective inhibition of aromatase
Th ere are several reasons by which AI may fail to inhibit 
 aromatase eﬀ ectively and residual oestrogen may main-
tain tumour growth. These include poor drug 
potency, adverse pharmocokinetics/pharmacogenetics, 
Figure 2. Early changes in microarray expression of oestrogen-regulated genes (KIAA0101, IRS1 (insulin receptor substrate 1), SERPINA3, 
TFF1 and TFF3 (trefoil factors 1 and 3) and proliferation markers (CDC2, Cyclin B1, CKS2, thymidylate synthase (TYMS), proliferating 
cell nuclear antigen (PCNA)) associated with neoadjuvant treatment with letrozole in individual breast cancers clinically resistant to 
endocrine treatment. Red represents an increase in expression and green a decrease. Brightness of colour indicates degree of change, with the 
brightest colours representing the greatest change. The left-hand column represents an ER-negative tumour (-ve), the A columns illustrate tumours 
with a molecular resistant phenotype, the B columns cases exhibiting decreases in expression of oestrogen-regulated genes but not in proliferation-
related genes, and the C columns tumours showing molecular sensitivity in both oestrogen-regulated and proliferation-related gene expression.
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compensatory endocrine loops and altered aromatase 
phenotype. Early-generation AIs did not completely 
block oestrogen biosynthesis [3,4] whereas later 
generation AIs were potent and able to produce clinical 
responses in tumours resistant to inferior inhibitors (see 
[38] for details). Although measurable diﬀ erences in 
potency are apparent between the current generation of 
inhibitors, there is no direct evidence to suggest that this 
is associated with cross-resistance. Furthermore, in the 
absence of con found ing factors, eﬀ ective inhibition of 
aromatase by third generation inhibitors appears to occur 
in most postmenopausal patients [59,60], suggesting that 
in eﬀ ective suppression of oestrogen is only likely to be 
the cause of resistance in occasional cases.
Pharmacokinetics/pharmacogenomics may have adverse 
inﬂ uences on AIs [61]. Th ere are drug inter actions 
between tamoxifen and some AIs; concomitant adminis-
tration of tamoxifen with either anastrozole or letrozole 
decreases plasma levels of the AIs (letrozole by 30 to 40% 
and anastrozole by 20 to 30%). However, oestrogen 
suppression does not seem to be compromised [62,63] 
and clinical relevance is likely to be limited. High/raised 
levels of aromatase may prevent eﬀ ective blockade by 
inhibitors. For example, high levels of aromatase in the 
premenopausal ovary and compensatory feedback loops, 
which increase levels of gonadotrophins, are associated 
with ineﬀ ective inhibition of ovarian aromatase by AIs. 
Consequently, in premenopausal women, AIs are 
generally used with a luteinizing hormone releasing 
hormone (LHRH) agonist to block the rise in gonado-
trophins [64]. SNPs in the aromatase gene have been 
associated with resistance to AIs, suggesting an aroma-
tase phenotype that is resistant to AIs. Diﬀ erential 
sensitivity to AIs has been observed in some breast 
cancers, but it is comparatively rare and has not been 
associated with mutations in aromatase [65]. Finally, 
ineﬀ ective aromatase inhibition may be related to 
treatment compliance issues.
Alternative sources of oestrogen/oestrogenic hormones
AIs block endogenous synthesis of oestrogen but have no 
eﬀ ects on the synthesis of other steroid classes, which 
Figure 3. Mechanisms of oestrogen-stimulated growth (whereby androgen is aromatised into oestrogen, which interacts with and 
activates oestrogen receptor (ER) to stimulate proliferation and growth), aromatase inhibitor (AI)-induced response (whereby AIs 
block aromatization of androgens into oestrogens) and multiple potential mechanisms of resistance to AIs. Blocks represent sites of 
specifi c interactions: A, ineff ective inhibition of aromatase; B, alternative sources of oestrogen/oestrogenic hormones (ES); C, inherent oestrogen 
insensitivity (non-functional ER); D, ligand-independent activation of oestrogen signalling pathways; E, oestrogen signalling disconnected from 
tumour proliferation and growth; F, enhanced cell survival. Abbreviations: A, androgen precursor; CSF, cell survival factor; E, oestrogen; ER, oestrogen 
receptor; ER-P, activated (phosphorylated) ER; GF, growth factor; Prolif, proliferation; Resp, response.
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can interact with ER (such as adrenal androgens ) [2], and 
on exogenous oestrogens/oestrogenic compounds, in-
clud ing synthetic estrogens, industrial pollutants, and 
phytoestrogens. However, if these alternative sources of 
oestrogenic factors were a common cause of resistance to 
AIs, it might be expected that anti-oestrogens (which 
block the action of oestrogenic factors irrespective of 
source) would have superior clinical beneﬁ ts to AIs 
where as generally they do not [9-11,66]. Moreover, there 
is evidence that tamoxifen can act as an oestrogen to 
compromise the action of AIs. Th us, the experience of 
combining tamoxifen with anastrozole in the Arimidex, 
Tamoxifen Alone or in Combination (ATAC) trial was 
that disease-free survival in patients taking the combi-
nation of anastrozole plus tamoxifen was signiﬁ  cantly 
less than in those taking anastrozole alone (and similar to 
tamoxifen alone) [66]. Th e basis for this probably resides 
in the accentuation of the oestrogen agonist properties of 
tamoxifen [67-69], which become apparent in the low 
oestrogen environment produced by AIs.
Inherent oestrogen insensitivity (non-functional ER)
Stimulatory eﬀ ects of oestrogen on the growth of 
hormone-dependent breast cancers are mostly mediated 
through ERs. It is conﬁ rmed by the fact that AIs are 
unlikely to produce responses in ER-negative tumours 
[70]. However, many tumours resistant to AIs have ER-
positive phenotypes [71], and the major challenge is to 
comprehend why, if AIs produce eﬀ ective oestrogen 
deprivation, they do not result in tumour regression. One 
possibility is that ER is non-functional. RNAs encoding 
variant and mutant ERs have been reported in breast 
cancer [72]; abnormal receptors may bind oestrogens but 
not transmit a signal. Tumours with non-functional ERs 
would be inherently insensitive to hormone stimulation 
(and refractory to AI therapy) despite being ER-positive. 
Other critical components of ER signalling are co-
regulators [71]. Coregulator abnormalities or imbalance 
may dislocate signalling so that growth is independent of 
oestrogen and not susceptible to AIs.
Ligand-independent activation/stimulation of oestrogen 
signalling pathways
ER signalling may be activated independently of oestro-
gen [71]. For example, HER2 signalling can result in 
ligand-independent ER phosphorylation [40]. Although 
numbers of ER-positive HER2-positive tumours are small 
[46], other kinases such as MAPKs and insulin-like 
growth factor 1 receptor/AKT are capable of activating 
and supersensitizing ER signalling [12]. It is thus relevant 
that overexpression of MAPK has been found in breast 
cancers resistance to letrozole [52]. Th ese considerations 
underpin the proposed use of appropriate signal trans-
duction inhibitors in combination or sequence with AIs 
[12,52]. Involvement of ligand-independent ER signalling 
may also explain cases with lack of cross-resistance 
between AIs and anti-oestrogens.
Oestrogen signalling disconnected from tumour 
proliferation and growth
Certain breast cancers appear clinically resistant despite 
fully functional ER and eﬀ ective oestrogen deprivation. 
However, it may be that proliferation and growth are 
stimulated by oestrogen-independent pathways. In this 
setting, AI treatment would reduce expression of classi-
cally oestrogen-regulated genes but not those associated 
with cellular proliferation. Th e phenotype has been 
described in some breast cancers clinically resistant to 
neoadjuvant treatment with letrozole [13,58].
Cell survival
Most tumours that appear clinically resistant to AI are 
nevertheless molecularly sensitive to the drugs insofar as 
the expression of both oestrogen-regulated and pro lifera-
tion-associated genes and proteins decreases with 
treatment [13,14,58]. To explain this form of resistance, it 
is necessary to suggest that the therapeutic reduction in 
proliferation leaves residual cell cycling which, together 
with eﬃ  cient cell survival mechanisms, maintains 
tumour growth.
Adaption with treatment/outgrowth of 
hormone-insensitive cellular clones
Th is scenario suggests that at the outset of treatment, 
tumours may have a responsive phenotype or be 
composed of a mixture of AI-responsive and -resistant 
cells. Under the pressure of treatment either adaptive 
intracellular changes occur (transforming a responsive 
phenotype into one with resistant characteristics) or 
there is an outgrowth of resistant cellular clones (present 
at the outset of treatment) with a survival advantage over 
other cells that are susceptible to therapy. Th is type of 
mechanism would be particularly applicable to resistance 
secondary to an initial response or ‘acquired’ resistance. 
Adaptive changes with AI treatment, such as increased/
changed expression of HER2 and ER co-regulators and 
loss of ER, have been described (although most breast 
cancers with acquired resistance to AIs remain ER-
positive after treatment [12,71]).
Conclusion
In order to understand the nature of resistance to AIs, 
this review has drawn upon endocrine, molecular and 
pathological measurements made in clinical material 
taken before and after therapy with AIs and upon obser-
vations from clinical trials in which AIs have been given 
as treatment either alone or in combination with other 
targeted agents. Th e major message from these studies is 
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that no single reason can account for resistance in all 
cases and that there are multiple and diverse mechanisms 
by which breast cancers may avoid the restraints of AI 
therapy. Th e consequences of this are that a battery of 
tests and predictive markers may be needed in order to 
elucidate the nature of resistance in individual tumours 
and that if rational treatments to avoid or reverse 
resistance are based on an underlying mechanism, they 
also will be both varied and individually targeted.
In terms of general identiﬁ cation of resistance, assess-
ment of ER is essential. However, in ER-positive tumours, 
additional markers are needed both to identify resistance 
and pinpoint its nature. Status of ER signalling may be 
directly assessed by measuring the degree/type of ER 
phosphorylation and levels of ER coactivators/corepres-
sors, and indirectly by analyzing proﬁ les of oestrogen-
regulated genes. Measurement of proliferation markers, 
relevant growth factors, their receptors and kinase 
activity may complement the ER signalling assessment. 
Treatment adherence and eﬃ  ciency of aromatase inhibi-
tion may be monitored by measuring blood levels of 
drugs, oestrogen and other hormones, aromatase activity, 
pharmacokinetics of AIs and pharmacogenetics of 
aroma tase. As well as multiple assessments, dynamic 
measurements may be necessary - neoadjuvant studies 
indicate that most clinically resistant tumours show a 
variety of molecular responses and these may help 
identify more precisely the exact nature of resistance in 
individual tumours. Th is may entail sequential biopsies of 
tumour during treatment and, in the case of acquired 
resistance, at the time of recurrence.
If resistance to AIs occurs through a diverse set of 
mechanisms, it follows that therapy aimed at preventing 
or reversing resistance is to be designed rationally by 
targeting, and understanding of the speciﬁ c cause of 
resistance in individual cases will be necessary. In this 
respect, the use of neoadjuvant and short-term 
preoperative protocols may be particularly informative - 
AIs and other signal-transduction modifying agents can 
be administered to patients and the primary tumour 
monitored for molecular and pathological eﬀ ects. Th ese 
approaches are particularly promising because they may 
be coupled with new pathological methodologies and 
molecular techniques. A future can be envisaged in 
which patients may be selected for speciﬁ c treatment 
regimes after molecular proﬁ ling and phenotyping at 
genomic, transcriptomic and proteomic levels in tumour 
taken before treatment and after a short period of 
therapy. Th ese results will be used to detect early 
evidence of resistance and to select rational treatments to 
avoid resistance (by using appropriate targeting drugs 
either in combination or in sequence with AIs). Th ese 
measures can be expected to increase and prolong 
clinical beneﬁ ts of AIs whilst circumventing resistance.
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